2015年(英文)

  1. Aoki J, Numata A, Yamamoto E, Fujii E, Tanaka M, Kanamori H: Impact of human herpes virus-6 reactivation on outcome of allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant, 21:2017-22, 2015.
  2. Aoki T, Shimada K, Suzuki R, Izutsu K, Tomita A, Maeda Y, Takizawa J, Mitani K, Igarashi T, Sakai K, Miyazaki K, Mihara K, Ohmachi K, Nakamura N, Takasaki H, Kiyoi H, Nakamura S, Kinoshita T, Ogura M: High-dose chemotherapy followed by autologous stem cell transplantation for relapsed/refractory primary mediastinal large B-cell lymphoma. Blood Cancer J, 5:e372, 2015.
  3. Chihara D, Asano N, Ohmachi K, Nishikori M, Okamoto M, Sawa M, Sakai R, Okoshi Y, Tsukamoto N, Yakushijin Y, Nakamura S, Kinoshita T, Ogura M, Suzuki R: Ki-67 is a strong predictor of central nervous system relapse in patients with mantle cell lymphoma (MCL). Ann Oncol, 26:966-73, 2015.
  4. Hasan M, Fermaintt CS, Gao N, Sakai T, Miyazaki T, Jiang S, Li QZ, Atkinson JP, Morse HC 3rd, Lehrman MA, Yan N: Cytosolic Nuclease TREX1 Regulates Oligosaccharyltransferase Activity Independent of Nuclease Activity to Suppress Immune Activation. Immunity, 43:463-74, 2015.
  5. Hirokawa M, Sawada K, Fujishima N, Teramura M, Bessho M, Dan K, Tsurumi H, Nakao S, Urabe A, Fujisawa S, Yonemura Y, Kawano F, Oshimi K, Sugimoto K, Matsuda A, Karasawa M, Arai A, Komatsu N, Harigae H, Omine M, Ozawa K, Kurokawa M; PRCA Collaborative Study Group: Long-term outcome of patients with acquired chronic pure red cell aplasia (PRCA) following immunosuppressive therapy: a final report of the nationwide cohort study in 2004/2006 by the Japan PRCA collaborative study group. Br J Haematol,169:879-86, 2015
  6. Iriyama N, Fujisawa S, Yoshida C, Wakita H, Chiba S, Okamoto S, Kawakami K, Takezako N, Kumagai T, Inokuchi K, Ohyashiki K, Taguchi J, Yano S, Igarashi T, Kouzai Y, Morita S, Sakamoto J, Sakamaki H: Shorter halving time of BCR-ABL1 transcripts is a novel predictor for achievement of molecular responses in newly diagnosed chronic-phase chronic myeloid leukemia treated with dasatinib: results of the D-First study of Kanto CML Study Group. Am J Hematol, 90:282-7, 2015.
  7. Iriyama N, Fujisawa S, Yoshida C, Wakita H, Chiba S, Okamoto S, Kawakami K, Takezako N, Kumagai T, Inokuchi K, Ohyashiki K, Taguchi J, Yano S, Igarashi T, Kouzai Y, Morita S, Sakamoto J, Sakamaki H: Early cytotoxic lymphocyte expansion contributes to a deep molecular response to dasatinib in patients with newly diagnosed chronic myeloid leukemia in the chronic phase: Results of the D-First study. Am J Hematol, 90:819-24, 2015.
  8. Ishii Y, Tomita N, Suzuki T, Ishiyama Y, Kishimoto K, Yamamoto E, Koyama S, Hattori Y, Nakajima Y, Motohashi K, Takasaki H, Kawasaki R, Hashimoto C, Takemura S, Fujimaki K, Fujita H, Sakai R, Fujisawa S, Motomura S, Ishigatsubo Y: Dissemination pattern of extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue. Leuk Lymphoma, 56: 2750-2, 2015.
  9. Kurosawa S, Yamaguchi T, Mori T, Kanamori H, Onishi Y, Emi N, Fujisawa S, Kohno A, Nakaseko C, Saito B, Kondo T, Hino M, Nawa Y, Kato S, Mori A, Hashimoto A, Fukuda T: Patient-reported quality of life after allogeneic hematopoietic cell transplantation or chemotherapy for acute leukemia. Bone Marrow Transplant, 50:1241-9, 2015.
  10. Kusumoto S, Tanaka Y, Suzuki R, Watanabe T, Nakata M, Takasaki H, Fukushima N, Fukushima T, Moriuchi Y, Itoh K, Nosaka K, Choi I, Sawa M, Okamoto R, Tsujimura H, Uchida T, Suzuki S, Okamoto M, Takahashi T, Sugiura I, Onishi Y, Kohri M, Yoshida S, Sakai R, Kojima M, Takahashi H, Tomita A, Maruyama D, Atsuta Y, Tanaka E, Suzuki T, Kinoshita T, Ogura M, Mizokami M, Ueda R: Monitoring of Hepatitis B Virus (HBV) DNA asnd Risk of HBV Reactivation in B-cell Lymphoma: A Prospective Observational Study. Clin Infect Dis, 61:719-29, 2015.
  11. Miyashita K, Tomita N, Taguri M, Suzuki T, Ishiyama Y, Ishii Y, Nakajima Y, Numata A, Hattori Y, Yamamoto W, Miyazaki T, Tachibana T, Takasaki H, Matsumoto K, Hashimoto C, Takemura S, Yamazaki E, Fujimaki K, Sakai R, Motomura S, Ishigatsubo Y: Beta-2 microglobulin is a strong prognostic factor in patients with DLBCL receiving R-CHOP therapy. Leuk Res, 39:1187?91, 2015.
  12. Motohashi K, Fujisawa S, Onizuka M, Kako S, Sakaida E, Shono K, Tatara R, Doki N, Mori T, Sakura T, Aotsuka N, Fujii E, Tomita N, Kawai N, Saitoh T, Usuki K, Taguchi J, Watanabe R, Kobayashi S, Yano S, Kanamori H, Takahashi S, Okamoto S: Effect of the order of total body irradiation and cyclophosphamide administration on the outcome of allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant, 50:1476-9, 2015.
  13. Nakajima Y, Hattori Y, Ito S, Ohshima R, Kuwabara H, Machida S, Shirasugi Y, Miyazaki K, Sakai R, Tomita N, Ando K, Higashihara M, Ishigatsubo Y: Acute leukemia during pregnancy: an investigative survey of the past 11 years. Int J Lab Hematol, 37:174-80, 2015.
  14. Nakajima Y, Kuwabara H, Kishimoto K, Numata A, Motohashi K, Tachibana T, Tanaka M, Yamashita N, Ishigatsubo Y, Fujisawa S: Successful pregnancy and delivery via in vitro fertilization with cryopreserved and thawed embryo transfer in an acute myeloid leukemia patient after allogeneic bone marrow transplantation. Int J Hematol, 101:417-20, 2015.
  15. Nakajima Y, Tomita N, Itabashi M, Miyashita K, Watanabe R, Miyazaki T, Tachibana T, Takasaki H, Kawasaki R, Tanaka M, Hashimoto C, Yamazaki E, Taguchi J, Fujimaki K, Sakai R, Fujita H, Fujisawa S, Harano H, Motomura S, Ishigatsubo Y: Analysis of outcomes in patients with supra-diaphragmatic vs infra-diaphragmatic diffuse large B cell lymphoma treated with R-CHOP therapy. Leuk Res, 39:198-203, 2015.
  16. Nakasone H, Fukuda T, Kanda J, Mori T, Yano S, Kobayashi T, Miyamura K, Eto T, Kanamori H, Iwato K, Uchida N, Mori S, Nagamura-Inoue T, Ichinohe T, Atsuta Y, Teshima T, Murata M: Impact of conditioning intensity and TBI on acute GVHD after hematopoietic cell transplantation. Bone Marrow Transplant, 50:559-65 2015.
  17. Numata A, Itabashi M, Kishimoto K, Motohashi K, Hagihara M, Kuwabara H, Tanaka M, Kato H, Chiba S, Kunisaki R, Fujisawa S: Intestinal amoebiasis in a patient with acute graft-versus-host disease after allogeneic bone marrow transplantation successfully treated by metronidazole. Transpl Infect Dis, 17:886-9, 2015.
  18. Numata A, Kajiyama R, Itabashi M, Ishii Y, Yamamoto W, Motohashi K, Matsumoto K, Hagihara M, Ishigatsubo Y, Fujisawa S: Emergence of del(20q) in a patient in molecular remission of chronic myelogenous leukemia during imatinib treatment, with reduction following imatinib discontinuation. Leuk Lymphoma, 10:1-8, 2015.
  19. Sakai R, Cho SK, Nanki T, Watanabe K, Yamazaki H, Tanaka M, Koike R, Tanaka Y, Saito K, Hirata S, Amano K, Nagasawa H, Sumida T, Hayashi T, Sugihara T, Dobashi H, Yasuda S, Sawada T, Ezawa K, Ueda A, Fujii T, Migita K, Miyasaka N, Harigai M; REAL Study Group. Head-to-head comparison of the safety of tocilizumab and tumor necrosis factor inhibitors in rheumatoid arthritis patients (RA) in clinical practic: results from the registry of Japanese RA patients on biologics for long-term safety (REAL) registry. Arthritis Res Ther,17, 2015
  20. Shimizu H, Saitoh T, Machida S, Kako S, Doki N, Mori T, Sakura T, Kanda Y, Kanamori H, Miyawaki S, Okamoto S.: Allogeneic hematopoietic stem cell transplantation for adult patients with mixed phenotype acute leukemia: results of a matched-pair analysis. Eur J Haematol, 95:455-60, 2015.
  21. Tachibana T, Tanaka M, Hagihara M, Kawasaki R, Yamazaki E, Koharazawa H, Taguchi J, Tomita N, Fujimaki K, Sakai R, Fujita H, Fujisawa S, Maruta A, Ishigatsubo Y, Kanamori H: Clinical significance of the administration of cytarabine or thiotepa in addition to total body irradiation and cyclophosphamide for allogeneic hematopoietic cell transplantation in patients with acute leukemia. Int J Hematol, 102:451-9, 2015.
  22. Tachibana T, Tanaka M, Kenji M, Numata A, Kishimoto K, Nakajima Y, Kuwabara H, Ishigatsubo Y, Fujisawa S: Clinical significance of serum ferritin compared to liver iron content, measured using magnetic resonance imaging, after allogeneic hematopoietic cell transplantation. Journal of Hematopoietic Cell Transplantation, 4:47-51, 2015.
  23. Tachibana T, Yamamoto E, Kawasaki R, Koharazawa H, Ishibashi D, Nakajima Y, Tanaka M, Matsumoto K, Ishigatsubo Y, Fujisawa S: Successful Engraftment and Durable Graft-versus-host Disease Control with Haploidentical Peripheral Blood and a Short-term Conditioning Regimen for Primary Graft Failure. Intern Med, 54:2749-52, 2015.
  24. Takamatsu H, Honda S, Miyamoto T, Yokoyama K, Hagiwara S, Ito T, Tomita N, Iida S, Iwasaki T, Sakamaki H, Suzuki R, Sunami K: Changing trends in prognostic factors for patients with multiple myeloma after autologous stem cell transplantation during the immunomodulator drug/proteasome inhibitor era. Cancer Sci, 106:179-85, 2015.
  25. Takasaki H, Yamamoto W, Ishii Y, Takahashi H, Watanabe R, Harada T, Kawasaki R, Hashimoto C, Motomura S, Tomita N, Ishigatsubo Y, Sakai R: Post-treatment PET-CT may Predict the Prognosis of DLBCL with a Bulky Mass. Indian J Hematol Blood Transfus, 31:346-51, 2015.
  26. Takenaka K, Nishida T, Asano-Mori Y, Oshima K, Ohashi K, Mori T, Kanamori H, Miyamura K, Kato C, Kobayashi N, Uchida N, Nakamae H, Ichinohe T, Morishima Y, Suzuki R, Yamaguchi T, Fukuda T: Cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation is associated with a reduced risk of relapse in patients with acute myeloid leukemia who survived to day 100 after transplantation: the Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group. Biol Blood Marrow Transplant, 21:2008-16, 2015.
  27. Tanaka M, Kanamori H, Matsumoto K, Tachibana T, Numata A, Ohashi K, Kobayashi T, Nakaseko C, Kanda Y, Yamazaki E, Fujisawa S, Ooi J, Sakura T, Aotsuka N, Onoda M, Machida S, Kato J, Usuki K, Watanabe R, Taguchi J, Yano S, Saito T, Takahashi S, Sakamaki H, Okamoto S: Kanto Study Group for Cell Therapy. Clinical significance of pretransplant serum ferritin on the outcome of allogeneic hematopoietic SCT: a prospective cohort study by the Kanto Study Group for Cell Therapy. Bone Marrow Transplant, 50:727-33, 2015.
  28. Tomita N, Hattori Y, Fujisawa S, Hashimoto C, Taguchi J, Takasaki H, Sakai R, Tateishi U, Ishigatsubo Y: Post-therapy 18F-fluorodeoxyglucose positron emission tomography for predicting outcome in patients with peripheral T-cell lymphoma. Ann Hematol, 94:431-6, 2015.
  29. Tomita N, Kodama F, Tsuyama N, Sakata S, Takeuchi K, Ishibashi D, Koyama S, Ishii Y, Yamamoto W, Takasaki H, Maki M, Kuwabara H, Tanaka M, Hashimoto C, Yamazaki E, Koharazawa H, Fujimaki K, Sakai R, Fujisawa S, Ishigatsubo Y: Biweekly THP-COP therapy for newly diagnosed peripheral T-cell lymphoma. Hematol Oncol, 33:9-14, 2015.
  30. Tomita N, Suzuki T, Ishiyama Y, Miyashita K, Takahashi H, Numata A, Ito S, Motohashi K, Tachibana T, Takasaki H, Kawasaki R, Hagihara M, Hashimoto C, Yamazaki E, Taguchi J, Fujimaki K, Sakai R, Fujisawa S, Motomura S, Ishigatsubo Y: R-CHOP therapy alone for limited-stage follicular lymphoma. Leuk Res, 39:582-5, 2015.
  31. Tomita N, Taguri M, Hashimoto C, Takasaki H, Fujimaki K, Motomura S, Koharazawa H, Takemura S, Fujita H, Yamazaki E, Kawasaki R, Taguchi J, Sakai R, Fujisawa S, Hattori Y, Kanamori H, Yamamoto W, Harano H, Ogawa K, Ishigatsubo Y: Evaluation of soluble interleukin-2 receptor and serum lactate dehydrogenase in malignant lymphoma. Ann Hematol, 94:1935-7, 2015.
  32. Tomita N, Takasaki H, Ishiyama Y, Kishimoto K, Ishibashi D, Koyama S, Ishii Y, Takahashi H, Numata A, Watanabe R, Tachibana T, Ohshima R, Hagihara M, Hashimoto C, Takemura S, Taguchi J, Fujimaki K, Sakai R, Motomura S, Ishigatsubo Y: Intrathecal methotrexate prophylaxis and central nervous system relapse in diffuse large B-cell lymphoma patients following R-CHOP. Leuk Lymphoma, 56:725-9, 2015.
  33. Tomita S, Kikuti Y, Carreras J, Kojima M, Ando K, Takasaki H, Sakai R, Takata K, Yoshino T, Bea S, Campo E, Nakamura N: Genomic and immunohistochemical profiles of enteropathy-associated T-cell lymphoma in Japan. Mod Pathol, 28:1286-96, 2015.
  34. Worel N, Buser A, Greinix HT, Hagglund H, Navarro W, Pulsipher MA, Nicoloso de Faveri G, Bengtsson M, Billen A, Espino G, Fechter M, Giudice V, Holig K, Kanamori H, Kodera Y, Leitner G, Netelenbos T, Niederwieser D, van Walraven SM, Rocha V, Torosian T, Vergueiro C, Weisdorf D, Yabe H, Halter JP. Suitability criteria for adult related donors: A consensus statement from the Worldwide Network for Blood and Marrow Transplantation (WBMT) Standing Committee on Donor Issues. Biol Blood Marrow Transplant, 21:2052-60, 2015.
  35. Yano S, Mori T, Kanda Y, Kato J, Nakaseko C, Fujisawa S, Tomita N, Sakai R, Shono K, Saitoh T, Aotsuka N, Kobayashi N, Saito T, Takahashi S, Kanamori H, Okamoto S; Kanto Study Group for Cell Therapy (KSGCT): Favorable survival after allogeneic stem cell transplantation with reduced-intensity conditioning regimens for relapsed/refractory follicular lymphoma. Bone Marrow Transplant, 50:1299-305, 2015.
ページトップへ